GRFS
Grifols, S.A. NASDAQ Listed Jun 2, 2011$7.40
-0.80%
vs $7.46
Mkt Cap $5.0B
52w Low $7.32
2.3% of range
52w High $10.85
50d MA $7.96
200d MA $8.78
P/E (TTM)
13.0x
EV/EBITDA
7.2x
P/B
0.7x
Debt/Equity
1.7x
ROE
—
P/FCF
6.7x
RSI (14)
34.50
ATR (14)
$0.17
Beta
1.21
50d MA
$7.96
200d MA
$8.78
Avg Volume
644.4K
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Avinguda de la Generalitat, 152 · Barcelona, NY 08174 · ES
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.29 | 0.29 | -0.3% | 8.96 | -2.9% | +1.6% | -0.1% | -5.0% | +0.2% | -0.8% | — |
| Nov 4, 2025 | AMC | 0.24 | 0.22 | -9.6% | 9.22 | -3.7% | -6.4% | -3.1% | +1.0% | +1.9% | +1.5% | — |
| Jul 28, 2025 | AMC | 0.23 | 0.19 | -17.4% | 10.09 | -0.2% | +4.1% | +3.3% | -1.4% | +0.7% | -0.6% | — |
| May 12, 2025 | AMC | 0.14 | 0.10 | -28.6% | 7.73 | +1.0% | +1.7% | -3.7% | +3.7% | -1.1% | +3.1% | — |
| Mar 6, 2025 | AMC | 0.13 | 0.26 | +100.0% | 8.50 | -0.8% | -0.8% | -7.5% | -0.9% | +0.4% | -0.5% | — |
| Nov 7, 2024 | AMC | 0.22 | 0.16 | -27.3% | 9.50 | +4.8% | -0.1% | -1.8% | -2.4% | -0.1% | +5.1% | — |
| Jul 30, 2024 | AMC | 0.23 | 0.02 | -91.3% | 7.75 | +1.9% | -3.6% | +2.3% | -0.8% | -4.1% | -0.4% | — |
| May 14, 2024 | AMC | 0.15 | 0.07 | -53.3% | 7.47 | +1.5% | +2.9% | -0.3% | +0.4% | -0.3% | -0.1% | — |
| Mar 5, 2024 | AMC | 0.22 | 0.14 | -36.4% | 6.17 | -12.6% | -11.3% | +2.6% | +24.8% | -3.3% | -7.1% | — |
| Nov 2, 2023 | AMC | 0.22 | 0.11 | -50.0% | 9.04 | +1.1% | +3.0% | -1.6% | -0.5% | +0.2% | -1.4% | — |
| Jul 27, 2023 | AMC | 0.20 | 0.09 | -54.8% | 10.00 | +0.0% | +6.0% | +2.9% | -6.0% | -1.6% | +2.2% | — |
| May 16, 2023 | AMC | 0.16 | -0.02 | -110.7% | 8.72 | -2.2% | -0.7% | +0.2% | +3.8% | +0.0% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 8 | JP Morgan | Maintains | Neutral → Neutral | — | $8.85 | $8.91 | +0.7% | +1.5% | -1.8% | +1.5% | +2.3% | -0.2% |
| Jun 17 | JP Morgan | Maintains | Neutral → Neutral | — | $9.09 | $9.07 | -0.2% | -2.4% | -1.9% | +0.8% | -4.6% | +2.0% |
| Mar 12 | Deutsche Bank | Downgrade | Hold → Sell | — | $6.77 | $6.68 | -1.3% | -7.1% | +0.8% | -9.1% | +6.4% | -1.3% |
| Dec 5 | JP Morgan | Maintains | Neutral → Neutral | — | $9.71 | $9.72 | +0.1% | +0.5% | +2.5% | +2.5% | +1.2% | -1.8% |
| Nov 5 | Deutsche Bank | Downgrade | Buy → Hold | — | $12.49 | $12.40 | -0.7% | -2.2% | +2.3% | -1.6% | +0.0% | -2.0% |
| Mar 23 | Credit Suisse | Upgrade | Neutral → Outperform | — | $16.00 | $16.50 | +3.1% | +4.9% | +0.8% | +3.1% | +1.0% | -1.6% |
| Mar 11 | HSBC | Upgrade | Hold → Buy | — | $15.15 | $15.85 | +4.6% | +5.7% | +0.4% | -0.2% | +0.4% | +2.9% |
| Oct 28 | Santander | Upgrade | Hold → Buy | — | $21.01 | $21.03 | +0.1% | +0.7% | +2.2% | -0.1% | +1.5% | +0.9% |
| Jun 27 | JP Morgan | Upgrade | Neutral → Overweight | — | $19.90 | $20.17 | +1.4% | +3.4% | +2.6% | -1.0% | +0.9% | +1.5% |
| Feb 8 | Berenberg | Downgrade | Buy → Hold | — | $19.21 | $18.24 | -5.0% | -6.2% | +0.9% | +3.3% | +1.2% | +0.2% |
| Jan 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $18.36 | $18.12 | -1.3% | -1.7% | +0.7% | +4.6% | -0.3% | +1.5% |
| Oct 1 | Morgan Stanley | Maintains | Underweight → Underweight | — | $21.37 | $21.47 | +0.5% | +0.1% | -1.4% | -2.5% | +2.2% | -0.3% |
| Mar 1 | Morgan Stanley | Maintains | Underweight → Underweight | — | $21.80 | $21.26 | -2.5% | -3.5% | -0.3% | +1.3% | +2.0% | -0.5% |
| Mar 17 | Nomura | Maintains | Buy → Buy | — | $15.09 | $15.14 | +0.3% | +0.2% | +0.3% | -0.1% | +0.6% | -0.6% |
| Feb 9 | Berenberg | Upgrade | Hold → Buy | — | $14.44 | $14.34 | -0.7% | +0.9% | -0.1% | -0.5% | +1.2% | +2.4% |
| Jan 4 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $16.20 | $16.00 | -1.2% | -1.4% | -0.8% | +1.6% | -3.2% | -1.2% |
| Dec 2 | HSBC | Downgrade | Buy → Hold | — | $17.30 | $17.33 | +0.2% | +0.6% | -0.5% | +1.6% | -1.4% | -1.5% |
| Nov 20 | Berenberg | Downgrade | Buy → Hold | — | $17.27 | $16.91 | -2.1% | -0.1% | +0.1% | -0.1% | +0.5% | +0.3% |
| Feb 12 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $17.14 | $16.67 | -2.7% | +0.2% | +0.9% | +0.6% | +0.1% | +1.8% |
| Mar 4 | JP Morgan | Upgrade | Neutral → Overweight | — | $20.39 | $20.62 | +1.1% | +1.5% | +0.3% | +2.1% | +1.0% | -0.4% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Capital World Investors | 22,924,990 | $184M | — | Mar 2026 |
| 2 | Morgan Stanley | 6,445,912 | $60M | Added | Dec 2025 |
| 3 | Millennium Management | 5,005,532 | $40M | Reduced | Mar 2026 |
| 4 | Bank Of America Corp /de/ | 4,327,413 | $35M | Added | Mar 2026 |
| 5 | Janus Henderson Group Plc | 3,290,089 | $26M | New | Mar 2026 |
| 6 | Ubs Group Ag | 3,156,653 | $25M | Added | Mar 2026 |
| 7 | Arrowstreet Capital, Limited Partnership | 2,723,385 | $22M | Reduced | Mar 2026 |
| 8 | Jpmorgan Chase & Co | 2,701,572 | $20M | Added | Mar 2026 |
| 9 | Bank Of Montreal /can/ | 2,506,278 | $20M | Reduced | Mar 2026 |
| 10 | Barclays Plc | 2,104,594 | $17M | Reduced | Mar 2026 |
| 11 | Sei Investments Co | 1,251,579 | $10M | Reduced | Mar 2026 |
| 12 | Wells Fargo & Company/mn | 1,053,433 | $8M | New | Mar 2026 |
| 13 | Royal Bank Of Canada | 785,703 | $6M | Added | Mar 2026 |
| 14 | Capital International Sarl | 645,251 | $5M | — | Mar 2026 |
| 15 | Saddlerock Capital Management Llc | 384,972 | $4M | New | Dec 2025 |
| 16 | Hudson Bay Capital Management Lp | 337,269 | $3M | Added | Dec 2025 |
| 17 | Credit Industriel Et Commercial | 361,455 | $3M | — | Mar 2026 |
| 18 | Quantinno Capital Management Lp | 352,798 | $3M | Added | Mar 2026 |
| 19 | Bi Asset Management Fondsmaeglerselskab A/s | 316,111 | $3M | Added | Mar 2026 |
| 20 | Groupe La Francaise | 238,928 | $2M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 16
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Brandes International Small Cap Equity Fund | 4,669,548 | $37M | Mar 2026 |
| 2 | Brandes Small Cap Value Fund | 1,318,045 | $11M | Mar 2026 |
| 3 | iShares Biotechnology ETF | 976,161 | $8M | Mar 2026 |
| 4 | Brandes International ETF | 801,724 | $7M | Dec 2025 |
| 5 | State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 341,628 | $3M | Mar 2026 |
| 6 | Brandes U.S. Small-Mid Cap Value ETF | 250,648 | $2M | Dec 2025 |
| 7 | Capital Group International Core Equity ETF | 120,713 | $1M | Feb 2026 |
| 8 | Brandes Global Equity Fund | 97,452 | $782K | Mar 2026 |
| 9 | Fidelity Nasdaq Composite Index Fund | 72,463 | $659K | Feb 2026 |
| 10 | ActivePassive International Equity ETF | 44,523 | $405K | Feb 2026 |
| 11 | Quantified Global Fund | 49,495 | $397K | Mar 2026 |
| 12 | Invesco Nasdaq Biotechnology ETF | 6,813 | $62K | Feb 2026 |
| 13 | Aquarius International Fund | 6,482 | $59K | Feb 2026 |
| 14 | Enterprise Mergers and Acquisitions Fund | 7,000 | $56K | Mar 2026 |
| 15 | ProShares Ultra Nasdaq Biotechnology | 5,633 | $51K | Feb 2026 |
| 16 | Avantis Total Equity Markets ETF | 652 | $6K | Feb 2026 |
Valuation
Market Cap
$5.04B
Enterprise Value
$11.60B
P/E (TTM)
12.98x
Forward P/E
8.45x
PEG Ratio
0.09x
P/B
0.66x
P/S
0.70x
P/FCF
6.70x
EV/EBITDA
7.16x
Shares Out
680.6M
Financials (TTM)
Revenue
$7.23B
Net Income
$386.1M
EBITDA
$1.62B
Free Cash Flow
$751.1M
Op Cash Flow
$1.01B
EPS Basic
$0.57
EPS Diluted
$0.57
EPS Forward
$0.88
Gross Margin
35.7%
Op Margin
16.4%
Net Margin
5.3%
Balance Sheet
Total Assets
$19.75B
Total Liab.
$12.13B
Total Equity
$7.60B
Cash
$824.6M
LT Debt
$7.39B
Book Value/Sh
$11.19
Debt/Equity
1.66x
Current Ratio
2.51
Quick Ratio
0.88
Returns & Growth
ROE
—
ROA
—
ROIC
5.3%
Rev Growth YoY
+0.2%
EPS Growth YoY
+147.8%
Price Returns
2W
+0.8%
1M
-4.7%
3M
-13.7%
6M
-11.3%
12M
-5.5%
Technicals
52W High
$10.85
52W Low
$7.32
50d MA
$7.96
200d MA
$8.78
RSI (14)
34.50
ATR (14)
$0.17
Beta
1.21
Avg Volume
644K
Dividends
Div Rate
$0.18
Div Yield
2.2%
Frequency
—
Ex-Div Date
Aug 12, 2025
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 10:45am
· Source: financialmodelingprep.com